CD33 and acute myeloid leukemia: Further, in vitro assays using primary samples from patients with AML or MDS have confirmed that Allo15CAR33-NKT cells can effectively deplete LSPCs that express low levels of CD33, unlike CAR33-T cells, which fail to effectively target these cells (Fig. 5o–s).